Government-Owned Inventions; Availability for Licensing, 76837-76838 [2023-24550]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm, where an agenda,
instructions for accessing the virtual NCAB
meetings, and any additional information for
the meetings will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–24578 Filed 11–6–23; 8:45 am]
BILLING CODE 4140–01–P
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Contact Person: Christopher D. Kane,
Ph.D., Health Science Administrator and
Program Officer, Office of Scientific
Operations, NCI at Frederick, National
Cancer Institute, National Institutes of
Health, 1050 Boyles Street, Building 427,
Room 4, Frederick, Maryland 21702,
christopher.kane@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: FNLAC:
https://deainfo.nci.nih.gov/advisory/fac/
fac.htm, where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2023–24584 Filed 11–6–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Meeting
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
The meeting will be held virtually
and is open to the public. Individuals
who plan to view the virtual meeting
and need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The meeting will be videocast
and can be accessed from the NIH
Videocasting and Podcasting website
(https://videocast.nih.gov).
Name of Committee: Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
Date: February 29, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: Ongoing and new activities at the
Frederick National Laboratory for Cancer
Research.
VerDate Sep<11>2014
16:30 Nov 06, 2023
Jkt 262001
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or
peter.tung@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
Technology Transfer and Intellectual
SUMMARY:
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
76837
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Beta Globin Mimetic Peptides and
Their Use
Description of Technology: Feedback
vasodilation by endothelium-derived
nitric oxide (NO) is under the regulation
of globins. Inventors discovered that not
only the alpha globin but also the beta
globin subunits of hemoglobin are
expressed in the human artery wall,
with beta globin interacting directly
with endothelium-derived nitric oxide
synthase (eNOS). This discovery of
tetrameric hemoglobin binding to eNOS
has led inventors to develop novel
mimetic peptides that disrupt the
binding of beta globin to eNOS,
diminishing the ability of hemoglobin to
restrict NO release and thereby
enhancing NO-mediated feedback
vasodilation. These agents can be used
to increase NO signaling from
endothelial cells and thus inhibit,
prevent, or reverse vasoconstriction.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Novel peptides to treat vascular
diseases characterized by
vasoconstriction, excess alpha
adrenergic signaling, or insufficient
nitric oxide signaling. Applications
could range from cerebral vasospasm to
pulmonary hypertension, to chronic
kidney disease, to transfusion medicine,
to erectile dysfunction, and to exercise
physiology.
Competitive Advantages:
• New pathway for regulation of
vasoconstriction/vasodilation that is
separate from the pathways that current
products available for treating nitric
oxide deficiency target. Combination
therapy with current vasoconstriction/
vasodilation medications of different
mechanisms may be possible.
• Enhancement of NO release at the
junction between the endothelial cell
and smooth muscle cell may provide
greater potency and fewer off-target
effects than other forms of NO delivery.
Development Stage:
• Peptides have been tested in human
and canine arteries ex vivo.
E:\FR\FM\07NON1.SGM
07NON1
76838
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
Inventors: Drs. Hans Ackerman
(NIAID), Steven Brooks (NIAID), Phillip
Cruz (NIAID), Rolf Swenson (NHLBI).
Publications: Brooks, SD et al.
‘‘Hemoglobin Interacts with Endothelial
Nitric Oxide Synthase to Regulate
Vasodilation in Human Resistance
Arteries’’ https://doi.org/10.1101/
2021.04.06.21255004 (This article is a
preprint and has not been certified by
peer review).
Intellectual Property: HHS Reference
No. E–060–2022–0–US–01; U.S.
Provisional Application No. 63/328,615,
filed on April 7, 2022; HHS Reference
No. E–060–2022–0–PCT–02; PCT
Application No. PCT/US2023/065432,
filed on April 6, 2023.
Licensing Contact: To license this
technology, please contact Peter Tung at
240–669–5483 or peter.tung@nih.gov,
and reference E–060–2022.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the invention. For
collaboration opportunities, please
contact Peter Tung at 240–669–5483, or
peter.tung@nih.gov.
Dated: November 1, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–24550 Filed 11–6–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–7070–N–80]
30-Day Notice of Proposed Information
Collection: Youth Homeless Systems
Improvement (YHSI) Program; OMB
Control No.: 2506–0219
Office of Policy Development
and Research, Chief Data Officer, HUD.
ACTION: Notice.
AGENCY:
HUD is seeking approval from
the Office of Management and Budget
SUMMARY:
Submission documents
khammond on DSKJM1Z7X2PROD with NOTICES
Component 1. Project Selection:
YHSI Project Selection Narratives ................
SF–424—Application for Federal Assistance
SF–424B Assurances for Non-Construction
Programs ...................................................
HUD–2880, Applicant/Recipient Disclosure/
Update Report ...........................................
HUD–424–CBW, Grant Application Detailed
Budget Worksheet .....................................
OMB–SF–LLL—Disclosure of Lobbying Activities (where applicable) ..........................
16:30 Nov 06, 2023
Responses
frequency
(average)
Number of
respondents
Information Collection
VerDate Sep<11>2014
(OMB) for the information collection
described below. In accordance with the
Paperwork Reduction Act, HUD is
requesting comment from all interested
parties on the proposed collection of
information. The purpose of this notice
is to allow for an additional 30 days of
public comment.
DATES: Comments Due Date: December
7, 2023.
ADDRESSES: Interested persons are
invited to submit comments regarding
this proposal. Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Interested persons are
also invited to submit comments
regarding this proposal and comments
should refer to the proposal by name
and/or OMB Control Number and
should be sent to: Colette Pollard,
Clearance Officer, REE, Department of
Housing and Urban Development, 451
7th Street SW, Room 8210, Washington,
DC 20410–5000; email
PaperworkReductionActOffice@
hud.gov.
FOR FURTHER INFORMATION CONTACT:
Colette Pollard, Reports Management
Officer, REE, Department of Housing
and Urban Development, 451 7th Street
SW, Washington, DC 20410; email
Colette.Pollard@hud.gov; telephone
number (202) 402–3400. This is not a
toll-free number. HUD welcomes and is
prepared to receive calls from
individuals who are deaf or hard of
hearing, as well as individuals with
speech or communication disabilities.
To learn more about how to make an
accessible telephone call, please visit
https://www.fcc.gov/consumers/guides/
telecommunications-relay-service-trs.
Copies of available documents
submitted to OMB may be obtained
from Ms. Pollard.
SUPPLEMENTARY INFORMATION: This
notice informs the public that HUD is
seeking approval from OMB for the
Jkt 262001
Total annual
responses
information collection described in
Section A.
The Federal Register notice that
solicited public comment on the
information collection for a period of 60
days was published on March 20, 2023
at 88 FR 16648.
Overview of Information Collection
Title of Information Collection: Youth
Homeless Systems Improvement (YHSI).
OMB Approval Number: 2506–0219.
Type of Request: Revision.
Form Number: HUD 2880, SF–LLL,
SF–424, SF–424B, HUD–424–CBW
Description of the need for the
information and proposed use: Congress
appropriated funds to the Department of
Housing and Urban Development in
FY2022 and in FY2023 to competitively
award funds to selected communities to
develop projects that implement
systems infrastructure to better address
youth homelessness. The YHSI projects
will focus on systems change to create
and build capacity for Youth Action
Boards; collect and use data from
different systems to improve the youth
homeless response system; develop
strong leaders within a community; and
improve the coordination,
communication, operation, and
administration of homeless assistance
projects, including prevention and
diversion strategies. This information
collection revision is to competitively
award YHSI funds to communities and
monitor the progress of the funded
project. This revision is to include two
additional forms in the approved PRA
for this program—the HUD–2880,
Applicant/Recipient Disclosure/Update
Report, and the 424–CBW Grant
Application Detailed Budget Worksheet.
Respondents: Not-for-profit
institutions; State, Local or Tribal
Governments.
Estimated Number of Respondents:
150.
Estimated Number of Responses: 190.
Frequency of Response: Biannual.
Average Hours per Response: 27.
Total Estimated Burdens: 2,670.
Burden hours
per response
Total hours
Hourly rate
Burden cost
per
instrument
100
100
1
1
100
100
22
0
2,200
0
$53.67
53.67
$118,074.00
0.00
100
1
100
0
0
53.67
0.00
100
1
100
0
0
53.67
0.00
100
1
100
0
0
53.67
0.00
100
1
100
0
0
53.67
0.00
PO 00000
Frm 00120
Fmt 4703
Sfmt 4703
E:\FR\FM\07NON1.SGM
07NON1
]]>Agencies
[Federal Register Volume 88, Number 214 (Tuesday, November 7, 2023)]
[Notices]
[Pages 76837-76838]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24550]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
[email protected]. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
Technology Transfer and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane,
Rockville, MD, 20852; tel. 301-496-2644. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
patent applications related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows.
Beta Globin Mimetic Peptides and Their Use
Description of Technology: Feedback vasodilation by endothelium-
derived nitric oxide (NO) is under the regulation of globins. Inventors
discovered that not only the alpha globin but also the beta globin
subunits of hemoglobin are expressed in the human artery wall, with
beta globin interacting directly with endothelium-derived nitric oxide
synthase (eNOS). This discovery of tetrameric hemoglobin binding to
eNOS has led inventors to develop novel mimetic peptides that disrupt
the binding of beta globin to eNOS, diminishing the ability of
hemoglobin to restrict NO release and thereby enhancing NO-mediated
feedback vasodilation. These agents can be used to increase NO
signaling from endothelial cells and thus inhibit, prevent, or reverse
vasoconstriction.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Novel peptides to treat vascular diseases characterized by
vasoconstriction, excess alpha adrenergic signaling, or insufficient
nitric oxide signaling. Applications could range from cerebral
vasospasm to pulmonary hypertension, to chronic kidney disease, to
transfusion medicine, to erectile dysfunction, and to exercise
physiology.
Competitive Advantages:
New pathway for regulation of vasoconstriction/
vasodilation that is separate from the pathways that current products
available for treating nitric oxide deficiency target. Combination
therapy with current vasoconstriction/vasodilation medications of
different mechanisms may be possible.
Enhancement of NO release at the junction between the
endothelial cell and smooth muscle cell may provide greater potency and
fewer off-target effects than other forms of NO delivery.
Development Stage:
Peptides have been tested in human and canine arteries ex
vivo.
[[Page 76838]]
Inventors: Drs. Hans Ackerman (NIAID), Steven Brooks (NIAID),
Phillip Cruz (NIAID), Rolf Swenson (NHLBI).
Publications: Brooks, SD et al. ``Hemoglobin Interacts with
Endothelial Nitric Oxide Synthase to Regulate Vasodilation in Human
Resistance Arteries'' https://doi.org/10.1101/2021.04.06.21255004 (This
article is a preprint and has not been certified by peer review).
Intellectual Property: HHS Reference No. E-060-2022-0-US-01; U.S.
Provisional Application No. 63/328,615, filed on April 7, 2022; HHS
Reference No. E-060-2022-0-PCT-02; PCT Application No. PCT/US2023/
065432, filed on April 6, 2023.
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or [email protected], and reference E-060-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the invention. For collaboration
opportunities, please contact Peter Tung at 240-669-5483, or
[email protected].
Dated: November 1, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-24550 Filed 11-6-23; 8:45 am]
BILLING CODE 4140-01-P
